Cargando…
Molecular insights into the improved clinical performance of PEGylated interferon therapeutics: a molecular dynamics perspective
PEGylation is a widely adopted process to covalently attach a polyethylene glycol (PEG) polymer to a protein drug for the purpose of optimizing drug clinical performance. While the outcomes of PEGylation in imparting pharmacological advantages have been examined through experimental studies, the und...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077387/ https://www.ncbi.nlm.nih.gov/pubmed/35541455 http://dx.doi.org/10.1039/c7ra12480e |
_version_ | 1784702108733276160 |
---|---|
author | Xu, Dong Smolin, Nikolai Shaw, Rance K. Battey, Samuel R. Tao, Aoxiang Huang, Yuying Rahman, Shaikh Emdadur Caylor, Matthew L. |
author_facet | Xu, Dong Smolin, Nikolai Shaw, Rance K. Battey, Samuel R. Tao, Aoxiang Huang, Yuying Rahman, Shaikh Emdadur Caylor, Matthew L. |
author_sort | Xu, Dong |
collection | PubMed |
description | PEGylation is a widely adopted process to covalently attach a polyethylene glycol (PEG) polymer to a protein drug for the purpose of optimizing drug clinical performance. While the outcomes of PEGylation in imparting pharmacological advantages have been examined through experimental studies, the underlying molecular mechanisms remain poorly understood. Using interferon (IFN) as a representative model system, we carried out comparative molecular dynamics (MD) simulations of free PEGx, apo-IFN, and PEGx-IFN (x = 50, 100, 200, 300) to characterize the molecular-level changes in IFN introduced by PEGylation. The simulations yielded molecular evidence directly linked to the improved protein stability, bioavailability, retention time, as well as the decrease in protein bioactivity with PEG conjugates. Our results indicate that there is a tradeoff between the benefits and costs of PEGylation. The optimal PEG chain length used in PEGylation needs to strike a good balance among the competing factors and maximizes the overall therapeutic efficacy of the protein drug. We anticipate the study will have a broad implication for protein drug design and development, and provide a unique computational approach in the context of optimizing PEGylated protein drug conjugates. |
format | Online Article Text |
id | pubmed-9077387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | The Royal Society of Chemistry |
record_format | MEDLINE/PubMed |
spelling | pubmed-90773872022-05-09 Molecular insights into the improved clinical performance of PEGylated interferon therapeutics: a molecular dynamics perspective Xu, Dong Smolin, Nikolai Shaw, Rance K. Battey, Samuel R. Tao, Aoxiang Huang, Yuying Rahman, Shaikh Emdadur Caylor, Matthew L. RSC Adv Chemistry PEGylation is a widely adopted process to covalently attach a polyethylene glycol (PEG) polymer to a protein drug for the purpose of optimizing drug clinical performance. While the outcomes of PEGylation in imparting pharmacological advantages have been examined through experimental studies, the underlying molecular mechanisms remain poorly understood. Using interferon (IFN) as a representative model system, we carried out comparative molecular dynamics (MD) simulations of free PEGx, apo-IFN, and PEGx-IFN (x = 50, 100, 200, 300) to characterize the molecular-level changes in IFN introduced by PEGylation. The simulations yielded molecular evidence directly linked to the improved protein stability, bioavailability, retention time, as well as the decrease in protein bioactivity with PEG conjugates. Our results indicate that there is a tradeoff between the benefits and costs of PEGylation. The optimal PEG chain length used in PEGylation needs to strike a good balance among the competing factors and maximizes the overall therapeutic efficacy of the protein drug. We anticipate the study will have a broad implication for protein drug design and development, and provide a unique computational approach in the context of optimizing PEGylated protein drug conjugates. The Royal Society of Chemistry 2018-01-09 /pmc/articles/PMC9077387/ /pubmed/35541455 http://dx.doi.org/10.1039/c7ra12480e Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | Chemistry Xu, Dong Smolin, Nikolai Shaw, Rance K. Battey, Samuel R. Tao, Aoxiang Huang, Yuying Rahman, Shaikh Emdadur Caylor, Matthew L. Molecular insights into the improved clinical performance of PEGylated interferon therapeutics: a molecular dynamics perspective |
title | Molecular insights into the improved clinical performance of PEGylated interferon therapeutics: a molecular dynamics perspective |
title_full | Molecular insights into the improved clinical performance of PEGylated interferon therapeutics: a molecular dynamics perspective |
title_fullStr | Molecular insights into the improved clinical performance of PEGylated interferon therapeutics: a molecular dynamics perspective |
title_full_unstemmed | Molecular insights into the improved clinical performance of PEGylated interferon therapeutics: a molecular dynamics perspective |
title_short | Molecular insights into the improved clinical performance of PEGylated interferon therapeutics: a molecular dynamics perspective |
title_sort | molecular insights into the improved clinical performance of pegylated interferon therapeutics: a molecular dynamics perspective |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077387/ https://www.ncbi.nlm.nih.gov/pubmed/35541455 http://dx.doi.org/10.1039/c7ra12480e |
work_keys_str_mv | AT xudong molecularinsightsintotheimprovedclinicalperformanceofpegylatedinterferontherapeuticsamoleculardynamicsperspective AT smolinnikolai molecularinsightsintotheimprovedclinicalperformanceofpegylatedinterferontherapeuticsamoleculardynamicsperspective AT shawrancek molecularinsightsintotheimprovedclinicalperformanceofpegylatedinterferontherapeuticsamoleculardynamicsperspective AT batteysamuelr molecularinsightsintotheimprovedclinicalperformanceofpegylatedinterferontherapeuticsamoleculardynamicsperspective AT taoaoxiang molecularinsightsintotheimprovedclinicalperformanceofpegylatedinterferontherapeuticsamoleculardynamicsperspective AT huangyuying molecularinsightsintotheimprovedclinicalperformanceofpegylatedinterferontherapeuticsamoleculardynamicsperspective AT rahmanshaikhemdadur molecularinsightsintotheimprovedclinicalperformanceofpegylatedinterferontherapeuticsamoleculardynamicsperspective AT caylormatthewl molecularinsightsintotheimprovedclinicalperformanceofpegylatedinterferontherapeuticsamoleculardynamicsperspective |